Navigation Links
Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C
Date:4/17/2011

MYSTIC, Conn. and DUBLIN, April 18, 2011 /PRNewswire/ -- Amarin Corporation plc (Nasdaq: AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from its ANCHOR trial for the Company's lead product candidate, AMR101. The Phase 3 trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses.

The purpose of the ANCHOR trial was to demonstrate that AMR101 is effective in reducing triglyceride levels in patients with high triglycerides without increasing LDL-C ("bad cholesterol") levels in patients on background statin therapy. The ANCHOR trial investigated AMR101 as a treatment for high triglycerides (≥200 and <500mg/dL) in 702 patients with mixed dyslipidemia (two or more lipid disorders) on background statin therapy at LDL-C (low-density lipoprotein cholesterol) goal who were at high risk of cardiovascular disease. The majority of these patients were diabetic (73%). This is the largest trial with omega-3 therapy conducted in this important patient population. All patients were on background statin therapy with simvastatin, atorvastatin or rosuvastatin. Despite the benefits of statin therapy, patients in this population have significant residual risk for cardiovascular events. The trial's primary endpoint was defined as the percentage change in triglyceride levels from baseline compared to placebo after twelve weeks of treatment. In addition, the study was powered to demonstrate a lack of LDL-C elevating effect with AMR101 compared to placebo. The trial was conducted under a Special Protocol Assessment (SPA) agreement with the FDA.

Triglyceride Reduction Levels Exceeded Company Expectations

The primary endpoint for triglyceride change was achieved at both 4 grams and 2 grams per day with median placebo-adjusted
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... -- Eli Lilly and Company (NYSE: LLY ) announced today ... for up to $1.6 billion aggregate principal amount of certain ... who tendered, and did not validly withdraw, their notes on ... time, on May 27, 2015 (the early tender date), ... to receive the total consideration. The total consideration for each ...
(Date:5/28/2015)... DUBLIN , May 28, 2015 /PRNewswire/ ... ) has announced the addition of Jain ... and Companies"  to their offering.  ... interference (RNAi) or gene silencing involves the ... inside the cell, this material is processed ...
(Date:5/28/2015)... May 28, 2015 AlloSource ®, ... cellular, bone, skin and soft-tissue allografts for use ... patient healing, today announced that AlloWrap® DS, its ... to the high-cost reimbursement category. ... and their patients," said Kimberly French , ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3AlloSource Announces Milestone In Reimbursement For AlloWrap DS 2
... WEBSTER, Texas, Nov. 10, 2011 IDEV Technologies, Incorporated ... for the company,s 6 French (6Fr) SUPERA VERITAS Transhepatic ... for sale outside the U.S. earlier this year, is ... the unique SUPERA stent, currently cleared in the U.S. ...
... Vascular Designs, Inc., a medical device manufacturing company, today ... FDA marketing clearance in 2009 – is now in ... in the treatment of liver cancer. The IsoFlow™ Infusion ... target and isolate areas within the body where the ...
Cached Medicine Technology:IDEV Technologies Receives FDA Clearance for Its SUPERA VERITAS® 6 French Stent Delivery System 2Breakthrough Cancer Treatment Now in Use at UC Davis Medical Center 2
(Date:5/29/2015)... Ca (PRWEB) May 29, 2015 ... pain consultations with specialists, physical therapy, and injections ... experiencing mid back and/or lower back pain, Healthpointe ... epidural injections for herniated discs, disc protrusions and ... . , Healthpointe’s team of renowned surgeons ...
(Date:5/29/2015)... 2015 The Global Allopurinol Industry ... on the current state of the Allopurinol industry.With ... statistics on the state of the industry and ... for companies and individuals interested in the market. ... industry including definitions, classifications, applications and industry chain ...
(Date:5/29/2015)... May 29, 2015 Designed with the ... up to create an all new, exclusive line of ... formulated with the latest and greatest, high impact, result ... to be effective. The 24/7 Series can be used ... and even the casual fitness enthusiasts. There are no ...
(Date:5/29/2015)... 29, 2015 Javlin continues to fulfill ... headquarters and a larger team, with the intention to ... market share in the U.S. and Canada. , Javlin ... achieved significant growth in 2014 with its strongest earnings ... data integration platform, CloverETL. To accelerate further progress and ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 This ... current state of the Naproxen industry.The report provides ... classifications, applications and industry chain structure. The ... international markets including development trends, competitive landscape analysis, ... are discussed as well as manufacturing processes and ...
Breaking Medicine News(10 mins):Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Allopurinol Industry (Global, China) 2015 Research Analysis and 2020 Forecasts 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 2Health News:BPI Sports and Bodybuilding.com Partner Up to Bring an Innovative New Line of Supplements 3Health News:Growth of Data Integration Platform CloverETL Continues in North America 2Health News:Naproxen Market Analysis For Global & China Regions 2020 Research Forecasts 2
... Group Upgrades from Allscripts Document Management; Expects ... Break-Even on Clinical & Financial Investment, CHICAGO ... leading provider of clinical software, connectivity and,information solutions ... The Heart Center Medical Group has selected the ...
... Medicare Fraud Strike Force, WASHINGTON, April 30 ... late yesterday of Medicare fraud,Assistant Attorney General Alice S. ... Acosta of the Southern District of Florida,announced today., ... Caos, 62, guilty on all,charged counts, including: conspiracy to ...
... PARK, Ohio, April 30 "Opportunities for,Next-Generation ... Medical,Devices Conference, will bring together the diverse ... cardiovascular, orthopaedic,neurological and pulmonary applications., Hosted ... world,s leading,materials society, this unique forum will ...
... Idiopathic pulmonary fibrosis (IPF) patients learn from specialists,seek ... The following announcement,was released by The Coalition ... Free Educational Seminar for Patients and Their,Families, ... with The,Coalition for Pulmonary Fibrosis (CPF), is hosting ...
... Pa., April 30 West Pharmaceutical,Services, Inc., (NYSE: ... 2008,Annual Meeting of Shareholders. The meeting will be held ... The live webcast can be accessed through the ... Please allow extra time prior,to the live webcast to ...
... for all holders of a valid press card / formal ... press facilities, including a working room, and the press office ... relevant experts. , You can register for ... direct any queries to the EULAR Press Office on ...
Cached Medicine News:Health News:The Heart Center Selects Allscripts Electronic Health Record and Practice Management for 50 Physicians 2Health News:The Heart Center Selects Allscripts Electronic Health Record and Practice Management for 50 Physicians 3Health News:The Heart Center Selects Allscripts Electronic Health Record and Practice Management for 50 Physicians 4Health News:Miami Jury Convicts Dermatologist of Medicare Fraud 2Health News:Medical Device Innovators to Discuss Next Generation of Implants at Cleveland Conference 2Health News:Pulmonary Fibrosis Patients Meet With Top Lung Doctors at Beth Israel Deaconess Medical Center 2Health News:Pulmonary Fibrosis Patients Meet With Top Lung Doctors at Beth Israel Deaconess Medical Center 3Health News:West Pharmaceutical Services, Inc. Announces Annual Meeting Webcast 2
Medium....
Goldman single hook....
These products are supplied non-sterile and must be sterilized before use. For insertion through the smokevac and nezhat-dorsey trumpet valve in conjunction with the universal instrument insert adapt...
The Accuref 8001 allows you to measure much smaller pupils than conventional units and 3 step Target light adjuster ensures accurate results....
Medicine Products: